Clinical outcomes and documentation of partial beneficial effects of immunotherapy for multiple sclerosis
- 1 January 1995
- journal article
- Published by Wiley in Annals of Neurology
- Vol. 37 (1) , 5-6
- https://doi.org/10.1002/ana.410370104
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Low‐dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosisAnnals of Neurology, 1995
- The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.Journal of Clinical Investigation, 1993
- Expanded clinical trials of treatments for multiple sclerosisAnnals of Neurology, 1993
- Low dose oral methotrexate treatment of multiple sclerosis: a pilot study.Journal of Neurology, Neurosurgery & Psychiatry, 1993
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- Long‐Term Prospective Study of Methotrexate in the Treatment of Rheumatoid ArthritisArthritis & Rheumatism, 1992
- A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosisNeurology, 1991
- Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double‐blinded, placebo‐controlled clinical trialAnnals of Neurology, 1990
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- Intensive Immunosuppression in Progressive Multiple SclerosisNew England Journal of Medicine, 1983